Dr. Jones is Principal Bioinformaticist and Scientific Advisor at Q2 Solutions | EA Genomics. He conducts collaborative scientific research in multiple areas, most recently in immuno-oncology. His background includes analysis, development and validation of the bioinformatic systems that process complex genomic assays, including next generation sequencing assays, evaluating new and emerging genomic technologies, and developing bioinformatic implementation strategies. He consults with clients and provides thought leadership in industry and public consortiums involved in genomic science and measurement. Dr. Jones has over 16 years of experience in advanced genomic technologies and 21 years of experience in scientific and technology leadership positions.
Clinical & Research Tools Showcase: Q2 Solutions | EA Genomics
EA Genomics, a division of Q2 Solutions, is a full-spectrum genomic services provider for clinical trials and research institutions.
Immune Landscape Signatures: Characterization of TME and Response to Therapy
Interplay between various immune cell activities in human tumors (both pro and anti-tumor) contributes to patient response to treatment using checkpoint inhibitors or other therapies (including targeted and standard chemotherapy). We have identified important gene expression-based Immune Landscape Signature (ILS) scores attributable to 11 key immune cell subtypes, individual genes and their ratios. The patient-specific scores from the ILS are used to determine immunogenic status of individual solid tumors and can be evaluated with other clinicopathological and tumor-specific genomic co-factors to understand and ultimately predict survival and individual patient response to therapies.